Granzyme B - Revision history

Dmitry Dzhagarov at 19:35, 25 August 2024

2024-08-25T19:35:28Z

← Older revision		Revision as of 19:35, 25 August 2024
Line 1:		Line 1:
	'''Granzymes''', a family of serine proteases with intracellular cytotoxic and/or proinflammatory functions, are increasingly recognized for their emerging roles in biological aging and disease.		'''Granzymes''', a family of serine proteases with intracellular cytotoxic and/or proinflammatory functions, are increasingly recognized for their emerging roles in biological aging and disease.
	Widely recognized as intracellular mediators of cell death, granzymes, particularly '''granzyme B (GzmB)''' is observed in numerous age-related conditions, also accumulate in the extracellular milieu of tissues with age, contributing to chronic tissue injury, inflammation, and impaired healing. Genetic deletion and/or pharmacological inhibition of granzyme B reduces premature aging and/or disease phenotypes in animal models.<ref>Richardson, K. C., Jung, K., Matsubara, J. A., Choy, J. C., & Granville, D. J. (2024). Granzyme B in aging and age-related pathologies. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2024.07.010</ref>		Widely recognized as intracellular mediators of cell death, granzymes, particularly '''granzyme B (GzmB)''' is observed in numerous age-related conditions, also accumulate in the extracellular milieu of tissues with age, contributing to chronic tissue injury, inflammation, and impaired healing. Genetic deletion and/or pharmacological inhibition of granzyme B reduces premature aging and/or disease phenotypes in animal models.<ref>Richardson, K. C., Jung, K., Matsubara, J. A., Choy, J. C., & Granville, D. J. (2024). Granzyme B in aging and age-related pathologies. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2024.07.010</ref>

			== VTI-1002, a small molecule, specific inhibitor against GzmB ==
			<ref>Shen, Y., Zeglinski, M. R., Turner, C. T., Raithatha, S. A., Wu, Z., Russo, V., ... & Granville, D. J. (2018). Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing. Experimental & molecular medicine, 50(5), 1-11. PMID: 29849046 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976625/ PMC5976625] DOI: 10.1038/s12276-018-0095-0</ref>

	[[Category:Aging pathways and hallmarks]]		[[Category:Aging pathways and hallmarks]]

Dmitry Dzhagarov at 19:22, 25 August 2024

2024-08-25T19:22:09Z

← Older revision		Revision as of 19:22, 25 August 2024
Line 5:		Line 5:
	[[Category:Drafts]]		[[Category:Drafts]]
	[[Category:Drugs]]		[[Category:Drugs]]
			[[Category:Glossary]]

Dmitry Dzhagarov: Created page with "'''Granzymes''', a family of serine proteases with intracellular cytotoxic and/or proinflammatory functions, are increasingly recognized for their emerging roles in biological aging and disease. Widely recognized as intracellular mediators of cell death, granzymes, particularly '''granzyme B (GzmB)''' is observed in numerous age-related conditions, also accumulate in the extracellular milieu of tissues with age, contributing to chronic tissue injury, inflammation, and i..."

2024-08-25T19:21:04Z

Created page with "'''Granzymes''', a family of serine proteases with intracellular cytotoxic and/or proinflammatory functions, are increasingly recognized for their emerging roles in biological aging and disease. Widely recognized as intracellular mediators of cell death, granzymes, particularly '''granzyme B (GzmB)''' is observed in numerous age-related conditions, also accumulate in the extracellular milieu of tissues with age, contributing to chronic tissue injury, inflammation, and i..."

New page

'''Granzymes''', a family of serine proteases with intracellular cytotoxic and/or proinflammatory functions, are increasingly recognized for their emerging roles in biological aging and disease.
Widely recognized as intracellular mediators of cell death, granzymes, particularly '''granzyme B (GzmB)''' is observed in numerous age-related conditions, also accumulate in the extracellular milieu of tissues with age, contributing to chronic tissue injury, inflammation, and impaired healing. Genetic deletion and/or pharmacological inhibition of granzyme B reduces premature aging and/or disease phenotypes in animal models.<ref>Richardson, K. C., Jung, K., Matsubara, J. A., Choy, J. C., & Granville, D. J. (2024). Granzyme B in aging and age-related pathologies. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2024.07.010</ref>

[[Category:Aging pathways and hallmarks]]
[[Category:Drafts]]
[[Category:Drugs]]